Analysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04497779 |
Recruitment Status :
Active, not recruiting
First Posted : August 4, 2020
Last Update Posted : June 8, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Asymptomatic COVID-19 Infection Laboratory-Confirmed Symptomatic COVID-19 Infection Laboratory-Confirmed | Procedure: Biospecimen Collection Other: Diagnostic Laboratory Biomarker Analysis Other: Electronic Health Record Review Other: Questionnaire Administration |
PRIMARY OBJECTIVES:
I. Establish a testing service for screening prospective donors of coronavirus disease 2019 (COVID-19) convalescent plasma (CCP).
II. Characterize the titer and neutralizing properties of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in CCP.
III. Correlate the SARS-CoV-2 antibody characteristics in CCP with the outcome in severely ill COVID-19 patients treated with CCP.
EXPLORATORY OBJECTIVES:
I. Facilitate the recruitment of CCP donors in medically underserved areas.
II. Develop high-throughput methods for detection/characterization of SARS-CoV-2 neutralizing and non-neutralizing antibodies.
III. Develop a bank of convalescent plasma that would be available for future studies relating to the content of CCP.
IV. Study the impact of antibody levels, donor characteristics and patient characteristics on outcome in COVID-19 patients treated with CCP.
V. Procure blood samples from COVID-19 convalescent volunteers for future COVID-19-related studies.
OUTLINE:
PROSPECTIVE CCP DONORS: Participants undergo collection of blood and/or nasopharyngeal swabs at the time of screening. Participants' medical records are reviewed.
CONVALESCENT BLOOD DONORS WHO CHOOSE NOT TO DONATE CCP: Participants undergo collection of blood sample at the time of screening. Participants' medical records are reviewed.
CCP RECIPIENTS: Patients undergo collection collection of blood samples at baseline, between CCP unit infusions, 24 hours after last CCP infusion, and between 14-28 after last CCP infusion. Patients' medical records are reviewed.
Study Type : | Observational |
Actual Enrollment : | 95 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Evaluation of Coronavirus Disease 19 (COVID-19) Convalescent Plasma |
Actual Study Start Date : | July 13, 2020 |
Estimated Primary Completion Date : | November 21, 2022 |
Estimated Study Completion Date : | August 21, 2023 |

Group/Cohort | Intervention/treatment |
---|---|
Screening (biospecimen collection, medical record review, CCP)
PROSPECTIVE CCP DONORS: Participants undergo collection of blood and/or nasopharyngeal swabs at the time of screening. Participants' medical records are reviewed. CONVALESCENT BLOOD DONORS WHO CHOOSE NOT TO DONATE CCP: Participants undergo collection of blood sample at the time of screening. Participants' medical records are reviewed. CCP RECIPIENTS: Patients undergo collection of blood samples at baseline, 12-24 hours after each CCP infusion, and 7 days after last CCP infusion. Patients' medical records are reviewed. |
Procedure: Biospecimen Collection
Undergo collection of blood and/or nasopharyngeal swabs Other: Diagnostic Laboratory Biomarker Analysis Correlative studies Other: Electronic Health Record Review Donors and recipients have their medical records reviewed. Other: Questionnaire Administration Ancillary studies |
- Convalescent plasma (CCP) units infused in coronavirus disease-2019 (COVID-19) patients [ Time Frame: Up to 12 months after enrollment ]Will be assayed for severe acute respiratory syndrome (SARS-CoV-2) immunoassay, coronavirus (CoV) PepSeq assay, and SARS-CoV-2 lenti-based neutralizing antibody titer.
- All-cause mortality [ Time Frame: At day 28 post-CCP infusion ]Will naturally be compared to reported data from the other studies. Analysis will focus on demonstrating that the antibody content of donor plasma increases the odds of surviving past day 28. Will also develop a nomogram for the probability of success (alive at day 28), accounting for patient, donor material and donor antibody characteristics measurable covariates.
- Donor antibody levels [ Time Frame: Up to 28 days post-CCP infusion ]Will be examined to see how this relates to the duration of hospitalization.
- Incidence of adverse events [ Time Frame: Up to 28 days post-CCP infusion ]Will be assessed on a 7-point ordinal scale, as recommended by the WHO patient outcome R&D Blueprint Group.
- CCP recipient outcomes [ Time Frame: Up to 28 days post-CCP infusion ]
Will be assessed on a 7-point ordinal scale. The scale is as follows:
- Death;
- Hospitalized, on invasive mechanical ventilation or ECMO;
- Hospitalized, on non-invasive ventilation or high flow oxygen devices;
- Hospitalized, requiring low flow supplemental oxygen;
- Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise);
- Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care (other than per protocol RDV administration);
- Not hospitalized
- Duration of hospitalization (days) [ Time Frame: Up to 28 days post-CCP infusion ]Patient can stay at the hospital for up to 28 days post-CCP infusion
- Time to clinical improvement (days) [ Time Frame: Up to 28 days post-CCP infusion ]Will be assessed on a 7-point ordinal scale.
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
For COVID-19 convalescent individuals:
- Age: ≥ 18 years
- Evidence of COVID-19 documented by a laboratory test either by: a diagnostic test (e.g., a NP swab) at the time of illness OR a positive serological test for SARS-CoV-2 antibodies after recovery, if prior diagnostic testing was not performed at the time COVID-19 was suspected.
Note: If volunteers can't provide evidence of COVID-19, but are otherwise eligible, then we will test them for SARS-CoV-2 antibodies to confirm eligibility.
- Be willing to complete a pre-screening questionnaire
- Be willing to donate blood samples
- Permit medical record review
- For prospective CCP donors only: weigh more than 110 pounds and be in general good health
For (COVID-19 convalescent plasma (CCP) recipients:
- Be enrolled in a clinical trial involving the infusion of CCP for the treatment of COVID-19.
- Be willing to provide blood samples
- Permit medical record review

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04497779
United States, California | |
City of Hope Medical Center | |
Duarte, California, United States, 91010 |
Principal Investigator: | John Zaia | City of Hope Medical Center |
Responsible Party: | City of Hope Medical Center |
ClinicalTrials.gov Identifier: | NCT04497779 |
Other Study ID Numbers: |
20204 NCI-2020-04000 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) 20204 ( Other Identifier: City of Hope Medical Center ) P30CA033572 ( U.S. NIH Grant/Contract ) TGen ( Other Identifier: Translational Genomics Research Institute (TGen) ) |
First Posted: | August 4, 2020 Key Record Dates |
Last Update Posted: | June 8, 2022 |
Last Verified: | September 2021 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Infections Communicable Diseases COVID-19 Laboratory Infection Disease Attributes Pathologic Processes Respiratory Tract Infections Pneumonia, Viral Pneumonia |
Virus Diseases Coronavirus Infections Coronaviridae Infections Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases Occupational Diseases |